>BTKi Adverse Events Managment in CLL and MCL
Managing Lymphoma is pleased to present this exciting new LIVE CME/CPE/CNE webinar series
Multidisciplinary Perspectives on BTK Inhibitors Adverse Events Management in CLL and MCL
Wait It Out, Dose Reduce, or Interrupt Therapy?
Earn 1.0 CME, CPE, or CNE credit hour

Pick a Date and Register Now!


Dr. Julie Vose Dr. Jeremy Stone Dr. Nicole Lamanna Dr. Peter Campbell
Julie M. Vose, MD, MB
Neumann M. and Mildred E.
Harris Professor
Chief, Division of Oncology/Hematology
University of Nebraska
Medical Center
Omaha, Nebraska
Jeremy R. Stone, MD
Assistant Professor of Cardiovascular Medicine
University of Nebraska
Medical Center
Omaha, Nebraska
Nicole Lamanna, MD
Associate Professor of Medicine
Chronic Lymphocytic
Leukemia Program
Columbia University
Medical Center
New York, New York
Peter Campbell, PharmD, BCOP
Clinical Pharmacy Manager
Program Director
Post-Graduate Year Two Oncology Pharmacy Residency
New York-Presbyterian Hospital
New York, New York

During the LIVE presentation and Q&A session, you will have the opportunity to submit questions via a message window. Following the LIVE presentation, the faculty will be available to respond to your questions.

Program Overview
Bruton’s Tyrosine Kinase inhibitor (BTKi) therapy has emerged as a major treatment option for patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL), mantle cell lymphoma (MCL) and other B-cell malignancies that can improve quality of life for patients. To ensure optimal patient outcomes, however, it is essential to maintain ongoing therapy. This requires prompt recognition and management of the unique adverse events (AEs) associated with BTKi therapy. However, data suggest that management of BTKi AEs by health care professionals (HCPs) often diverges from evidence-based expert recommendations, especially grade 3/4 AEs.


15 minutes Review of BTKi Therapy for the Treatment of CLL and MCL
40 minutes “How I Manage” Interactive Case Challenges and Practice Questions
5 minutes Conclusions/Q&A

Target Audience
This activity is designed for physicians, nurses, pharmacists and other clinicians who provide care for patients with CLL/SLL and MCL.

Learning Objectives
Upon completion of this educational activity, participants should be able to:

  • Select a BTKi therapy for patients with CLL/SLL and MCL, considering safety data and associated patient selection factors
  • Employ AE monitoring and management strategies for individual patients with CLL and MCL on BTKi therapies
  • Collaborate with the multidisciplinary team, such as hematology/oncology, cardiology, and rheumatology clinicians, to effectively support AE monitoring and management strategies


MediCom Worldwide, Inc. CME Credit
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

MediCom Worldwide, Inc. designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 1.0 contact hour of Continuing Education Credit. Universal Activity Number: 827-0000-21-028-L01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when claiming credit for a CPE program.
MediCom Worldwide, Inc. Nursing Credit
MediCom Worldwide, Inc., 101 Washington Street, Morrisville, PA 19067 is approved by the California Board of Registered Nursing, Provider Number CEP11380. MediCom designates this CNE activity for 1.0 contact hour. Program Number: 21-028-144

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosures
Dr. Julie Vose received honoraria related to formal advisory activities from AstraZeneca, and Pharmacyclics LLC, as well as consulting fees from AstraZeneca, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, Janssen Pharmaceuticals Inc., Johnson & Johnson Services, Inc., Pharmacyclics, and MorphoSys. She has received grant support related to research activities from AstraZeneca, Bristol-Myers Squibb, and Loxo Oncology.

Dr. Jeremy Stone has disclosed no relevant financial relationships.

Dr. Nicole Lamanna has received honoraria related to formal advisory activities from AbbVie Inc., AstraZeneca, BeiGene, Celgene Corporation ‒ A Bristol-Myers Squibb Company, Genentech - A Member of the Roche Group, Janssen Pharmaceuticals, Inc., and Pharmacyclics, Inc. She has received grant support related to research activities from AbbVie, AstraZeneca, BeiGene, Genentech, Loxo Oncology, MingSight Pharmaceuticals, Inc., Octapharma USA, Inc., Oncternal Therapeutics, TG Therapeutics, Inc., and Verastem, Inc.

Dr. Peter Campbell has disclosed no relevant financial relationships.

Planning Committee Disclosures
The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Joan Meyer, RN, MHA, Executive Director, Isabelle Vacher, Vice President of Educational Strategy, Scott J. Hershman, MD, FACEHP, CHCP, Educational Program Director, and Andrea Mathis, Project Manager, have no relevant financial relationships.

Instructions for Participation and Credit

There are no fees for participating in this activity.

In order to receive credit, all participants must complete the self-assessment post-test and Activity Evaluation following the activity. Partial credit will not be awarded for this activity. Participants must receive a minimum score of 70% on the self-assessment to qualify for CE credit.

Certificates for CME and CNE credit may be printed immediately after successfully completing the post-test and activity evaluation.

CPE Credit will be awarded upon completion of a self-assessment and evaluation. Participation verification must be completed within 4 weeks of the activity. Your online CPE certificate will be reported directly to CPE Monitor within 4 weeks of receiving post-activity documentation.

If you have any questions regarding this activity, please contact MediCom Worldwide, Inc. at 800-408-4242, x110 or cjacobus@medicaled.com.

Provided by
MediCom Worldwide, Inc.

Supported by educational grants from Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC and BeiGene, Ltd.
Sunshine Sickle Cell Project